An Introduction to Front-line Nivolumab/Ipilimumab Therapy for uHCC: The CheckMate 9DW Study.

James J. Harding, MD, reviews the ongoing phase 3 CheckMate 9DW trial, which is investigating nivolumab plus ipilimumab (NIVO + IPI) vs lenvatinib or sorafenib as first-line (1L) treatment for unresectable hepatocellular carcinoma (uHCC).

EP: 1.Evolving First-Line Treatment Strategies for uHCC.

Now Viewing

EP: 2.An Introduction to Front-line Nivolumab/Ipilimumab Therapy for uHCC: The CheckMate 9DW Study.

Video content above is prompted by the following:

Review the ongoing phase 3 CheckMate 9DW investigating nivolumab + ipilimumab (NIVO + IPI) vs lenvatinib or sorafenib in 1L uHCC.

Recent Videos